Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis
Morie A. Gertz(Medical University of South Carolina), Laura Obici(University of Pavia), Chafic Karam(Amyloidosis Foundation), Carol Whelan(The Royal Free Hospital), Brian Drachman(Penn Presbyterian Medical Center), Morton Scheinberg(Université Paris-Sud), Stephen B. Heitner(Brigham and Women's Hospital), Sami Khella(University of Lisbon), Márcia Waddington‐Cruz(Université Paris-Sud)
Cited by 39
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k